CRVO Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -- compared to CervoMed's net margin of -10571.43%. CervoMed's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

CervoMed has a consensus price target of $15.83, signalling upside risk potential of 47.84%. On the other hand AIM ImmunoTech has an analysts' consensus of $2.75 which suggests that it could grow by 1858.69%. Given that AIM ImmunoTech has higher upside potential than CervoMed, analysts believe AIM ImmunoTech is more attractive than CervoMed.

CervoMed has a beta of 1.837, which suggesting that the stock is 83.67% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.411, suggesting its less volatile than the S&P 500 by 58.887%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than AIM ImmunoTech quarterly revenues of $35K. CervoMed's net income of -$6.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, CervoMed's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 168.72x versus 38.58x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -- compared to CervoMed's net margin of 12.41%. CervoMed's return on equity of -- beat Boston Scientific's return on equity of 8.96%.

CervoMed has a consensus price target of $15.83, signalling upside risk potential of 47.84%. On the other hand Boston Scientific has an analysts' consensus of $115.62 which suggests that it could grow by 12.61%. Given that CervoMed has higher upside potential than Boston Scientific, analysts believe CervoMed is more attractive than Boston Scientific.

CervoMed has a beta of 1.837, which suggesting that the stock is 83.67% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.772, suggesting its less volatile than the S&P 500 by 22.845%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Boston Scientific quarterly revenues of $4.6B. CervoMed's net income of -$6.7M is lower than Boston Scientific's net income of $566M. Notably, CervoMed's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 82.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 168.72x versus 9.11x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Inovio Pharmaceuticals has a net margin of -- compared to CervoMed's net margin of -16566.39%. CervoMed's return on equity of -- beat Inovio Pharmaceuticals's return on equity of -119.02%.

CervoMed has a consensus price target of $15.83, signalling upside risk potential of 47.84%. On the other hand Inovio Pharmaceuticals has an analysts' consensus of $7.83 which suggests that it could grow by 316.67%. Given that Inovio Pharmaceuticals has higher upside potential than CervoMed, analysts believe Inovio Pharmaceuticals is more attractive than CervoMed.

CervoMed has a beta of 1.837, which suggesting that the stock is 83.67% more volatile than S&P 500. In comparison Inovio Pharmaceuticals has a beta of 0.917, suggesting its less volatile than the S&P 500 by 8.256%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inovio Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Inovio Pharmaceuticals pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Inovio Pharmaceuticals quarterly revenues of $117K. CervoMed's net income of -$6.7M is higher than Inovio Pharmaceuticals's net income of -$19.4M. Notably, CervoMed's price-to-earnings ratio is -- while Inovio Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 168.72x versus -- for Inovio Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Leap Therapeutics has a net margin of -- compared to CervoMed's net margin of --. CervoMed's return on equity of -- beat Leap Therapeutics's return on equity of --.

CervoMed has a consensus price target of $15.83, signalling upside risk potential of 47.84%. On the other hand Leap Therapeutics has an analysts' consensus of $3.00 which suggests that it could grow by 669.23%. Given that Leap Therapeutics has higher upside potential than CervoMed, analysts believe Leap Therapeutics is more attractive than CervoMed.

CervoMed has a beta of 1.837, which suggesting that the stock is 83.67% more volatile than S&P 500. In comparison Leap Therapeutics has a beta of 0.348, suggesting its less volatile than the S&P 500 by 65.246%.

CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Leap Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Leap Therapeutics pays out -- of its earnings as a dividend.

CervoMed quarterly revenues are --, which are smaller than Leap Therapeutics quarterly revenues of --. CervoMed's net income of -$6.7M is higher than Leap Therapeutics's net income of -$18.2M. Notably, CervoMed's price-to-earnings ratio is -- while Leap Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 168.72x versus 8.74x for Leap Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.